Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the anti-tumor activity of a small molecule inhibitor of TGFβ recept...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Yingling, Jonathan M., McMillen, William T., Yan, Lei, Huang, Huocong, Sawyer, J. Scott, Graff, Jeremy, Clawson, David K., Britt, Karen S., Anderson, Bryan D., Beight, Douglas W., Desaiah, Durisala, Lahn, Michael M., Benhadji, Karim A., Lallena, Maria J., Holmgaard, Rikke B., Xu, Xiaohong, Zhang, Faming, Manro, Jason R., Iversen, Philip W., Iyer, Chandrasekar V., Brekken, Rolf A., Kalos, Michael D., Driscoll, Kyla E.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Priority Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805504/
https://ncbi.nlm.nih.gov/pubmed/29467918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23795
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki